Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Yifan Pharmaceutical

AI overview

Sign in and the AI will write an overview from our coverage.

Headlines · 2

  1. Chinese Medical Companies Diversify Into AI and Semiconductor Funds

    TMTPost, publishing commentary from 医药研究社, reports that several Chinese listed medical and health companies are allocating capital to AI and semiconductor funds. Yifan Pharmaceutical and Tebao Biological each committed 100 million yuan to funds, although Yifan's announcement only specified emerging industries, while Yuwell Medical subscribed to a fund focused on AI, semiconductor chips and integrated circuits. BY-HEALTH separately invested 50 million yuan in Yuanli Semiconductor, illustrating a direct minority-stake route alongside fund investments.

    钛媒体 · 🔥 0
  2. Chinese medical firms queue up to invest in AI and semiconductor funds

    A report by VCBeat (carried by 36Kr and TMTPost) says that after Andon Health's "medical main business plus tech investment" model gained traction, a group of listed Chinese medical companies — including Yuwell Medical, EasyDiagnosis, Intco Medical, Yifan Pharmaceutical and Amoytop Biotech — have recently subscribed to funds focused on AI and semiconductors, with names such as Gaorong Changying Fund and the new Monolith fund backed by medical firms. The report says Andon Health's portfolio includes Moonshot AI, MetaX, StepFun and Zhengxing Innovation, and that its net profit rose 233.66% year on year in the first half of 2026. Specific moves include Yuwell Hong Kong putting HK$94.9 million into CFTC fund shares and a plan to commit up to 500 million yuan to a fund managed by SMIC Capital, while Intco, Amoytop and Yifan invested as limited partners. The report also cites an industry figure warning that AI and semiconductor asset valuations are already high and that increasing tech exposure now may not be the best window.

    36氪 人工智能 · 🔥 0

Experience and discussion from the community

Share my Yifan Pharmaceutical experienceAsk about Yifan Pharmaceutical

Nobody has shared their experience with Yifan Pharmaceutical yet.